Objective To investigate the clinical effect of transurethral bipolar plasma en bloc resection of bladder tumors (ERBT) in the treatment of nonmuscle invasive bladder cancer (NMIBC).Methods The clinical data of 79 patients treated in the department of urology of our hospital from January 2019 to June 2021 for NMIBC were retrospectively analyzed, including 39 patients in the observation group who received transurethral bipolar plasma ERBT and 40 patients in the control group who received conventional transurethral resection of bladder tumor (cTURBT). Bladder infusion chemotherapy with pirubicin hydrochloride was regularly performed after surgery. Urological ultrasound and cystoscopy were reexamined 3, 6, 12 and 24 months after surgery. The operative time, intraoperative blood loss, catheter indwelling time, intraoperative adverse events and postoperative recurrence were observed and compared between the two groups.Results There was no significant difference in the operative time, intraoperative blood loss, catheter indignant time and incidence of obturator emission between 2 groups (all P>0.05). The visible rate of detrusor muscle in observation group was higher than that in control group [92.3%（36/39）vs. 52.5%（21/40），P<0.05]. No perioperative hemorrhage or bladder perforation occurred in both groups. There were 5 cases of tumor recurrence in the observation group (12.8%, 5/39) and 14 cases in the control group (35.0%, 14/40). The total recurrence rate within 2 years was significantly different between the two groups (P<0.05). The 2-year recurrence rate of control group was higher than that of observation group (P<0.05).Conclusions Compared with cTURBT, ERBT is a safe and effective treatment method for NMIBC, and the visibility of muscle layer in histopathological specimens is significantly improved. Therefore, ERBT can be popularized in clinical application under the condition that indications are understood.
